Clinical Trial Update: Randomised Placebo-controlled Duloxetine-referenced Efficacy and Safety Study of 2.5, 5 and 10 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder [Phase 3]

View source ↗

Summary

Phase 3 randomized, placebo-controlled study assessing efficacy and safety of vortioxetine at 2.5, 5, and 10 mg for acute treatment of major depressive disorder…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• Brintellix (vortioxetine)
• Vortioxetine (vortioxetine)

Snippet

Sponsor: H. Lundbeck A/S | Conditions: Major Depressive Disorder | Phase 3 | Status: COMPLETED | Results posted: 2014-02-11